{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "CLOV",
  "name": "Clover Health Investments, Corp.",
  "url": "https://frontierpicks.com/dossiers/CLOV/",
  "json_url": "https://frontierpicks.com/dossiers/CLOV.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a6",
    "n": 6
  },
  "current_thesis": "Q2 (2026-08-05) resolved the binary upward — revenue $743.2M +56%, adj EBITDA $41M, FY guide lifted on every line to $2.92–3.00B revenue and $20–35M GAAP net income — but the 52-week high of $5.41 was sold to a $4.60 close on 2026-08-14 while CMS appealed the Star-Ratings ruling to the 11th Circuit on 2026-07-21. Maturing narrative, no dated catalyst until October.",
  "invalidation_trigger": "A weekly close below $4.23 refills the 2026-06-10 court-ruling gap and ends the Star-Ratings breakout leg; secondary conditions are an Eleventh Circuit order vacating the 4.5-Star recalculation, or Insurance BER printing above 87.6% at the Q3 report.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "managed-care-health-services",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "2026-07-06: Elevance filed suit seeking a recalculated Medicare Star Rating, following Clover's precedent — validates the legal theory but commoditizes CLOV's specific edge and crowds the quality-bonus pool.",
    "Former Social Capital Hedosophia III SPAC; retail-flow heritage with double-digit single-session moves (+18.9% on 2026-06-10).",
    "CMS filed a notice of appeal on 2026-07-21 — the court-ordered 4.5-Star rating sits with the Eleventh Circuit and is not final.",
    "FY2026 guide after the 2026-08-05 raise: revenue $2.92–3.00B, adjusted EBITDA $70–85M, GAAP net income $20–35M.",
    "Clover Care Services CEO Brady Priest stepped down 2026-06-16 with no successor named; home-care folded into broader operations.",
    "A 2026-07-04 anomalous-login incident was disclosed 2026-07-17 with 'no material impact' stated — an open monitoring item for a data-heavy insurer.",
    "Q3 2026 print expected early November (date unconfirmed); the usual pre-print disclosure blackout applies ahead of it."
  ],
  "body_markdown": "## Current Thesis\nThe binary flagged in the prior update resolved upward. Clover reported Q2 on 2026-08-05: revenue $743.2M (+56% YoY), GAAP net income $28M, adjusted EBITDA $41M, Insurance BER 87.6%, Medicare Advantage membership ~157,000 (+48% YoY) — and raised every line of the FY2026 guide, including GAAP net income from $0–20M to $20–35M. The thin-profitability objection that dominated the June–July frame was answered by the company's own numbers. What did not follow was continuation: the 52-week high sits at $5.41 and the 2026-08-14 close was $4.60, -15.0% from it, with RSI(14) at 57.9. Since the stock traded near $4.32 on 2026-07-24, the $5.41 print dates to the post-earnings window (inference from the price series, not a company disclosure) — meaning the best fundamental headline of the year marked the high and was sold. Layered on top: CMS filed a notice of appeal on 2026-07-21, moving *Clover Insurance Co. V. HHS* to the Eleventh Circuit, so the court-ordered 4.5-Star recalculation that produced the +18.9% session on 2026-06-10 is now under appellate review. The narrative leg on offer is a Medicare Advantage insurer compounding membership near 50% YoY with a court-won quality-bonus uplift — bought at mid-range, into a seven-week calendar void, with the legal pillar sub judice.\n\n## Bull Case\n- Q2 2026 (reported 2026-08-05): revenue $743.2M, +56% YoY; GAAP net income $28M; adjusted EBITDA $41M. Revenue cleared the $728.3M consensus cited on Benzinga's 2026-08-05 wire.\n- FY2026 guidance raised across the board: revenue $2.81–2.92B → $2.92–3.00B; adjusted EBITDA $50–70M → $70–85M; GAAP net income $0–20M → $20–35M. The adjusted EBITDA floor is now above the prior ceiling.\n- Insurance BER of 87.6% in Q2, roughly an 80bp YoY improvement attributed on the call to favorable medical-cost trend development — the specific line item that would have broken the thesis moved the right way.\n- MA membership ~157,000, +48% YoY, extending the Q1 pace (154,607 average, +51.6% YoY).\n- The rating uplift covers both contracts, not one: the 8-K filed 2026-06-18 (event 2026-06-17) disclosed PPO contract H5141 recalculated 3.5 → 4.5 Stars for payment year 2027, and CMS's system displaying HMO contract H8010 at 4.5 Stars, up from 4.0, also for payment year 2027. Modern Healthcare and Becker's put the recalculation's value at an estimated $120M in 2027 payments.\n- Sell-side marks stepped up after the print: UBS raised its target to $5.00 from $4.75 on 2026-08-06 (Neutral maintained); Canaccord's Buy and $5.50 target (raised 2026-07-21 from $4.20) stand.\n- Management framed the Counterpart Health / Clover Assistant licensing line as a growing non-insurance contributor on the 2026-08-05 call; no standalone revenue figure was broken out in the coverage reviewed.\n\n## Bear Case\n- CMS's 2026-07-21 notice of appeal puts the Star-Ratings judgment in front of the Eleventh Circuit. A reversal would reopen the quality-bonus math for payment year 2027 — the single largest identifiable driver of the June re-rating.\n- The tape topped on the good news. A 52-week high of $5.41 followed by a $4.60 close on 2026-08-14 is distribution into strength, and no new base has formed at the highs.\n- Upside to published marks is compressed: the highest target on the tape is $5.50 (Canaccord), the lowest $5.00 (UBS Neutral), and the average is $5.17 per S&P Global as carried by CNN Markets — against a $4.60 close. Three publishing analysts means one downgrade carries disproportionate weight.\n- An 87.6% benefit-expense ratio leaves a narrow buffer under a $20–35M FY GAAP net-income guide on $2.92–3.00B of guided revenue; a single quarter of utilization pressure consumes the raise.\n- Elevance's 2026-07-06 suit seeking its own recalculated Star Rating validates the legal theory while eroding its exclusivity. If the tactic generalizes across large MA carriers, the relative advantage of Clover's rating narrows.\n- Retail-flow heritage remains live: a +18.9% session on 2026-06-10 and a double-digit after-hours move on 2026-08-05 are the behaviour of a former Social Capital Hedosophia III listing, not of a settled managed-care compounder.\n\n## Setup & Price Structure\n- Reference close 2026-08-14: $4.60. 52-week high $5.41 (-15.0%). Three-month return +32.6%. RSI(14) 57.9 — neither stretched nor washed out.\n- $4.23 is the structural shelf: the pre-June 52-week high, gapped through on 2026-06-10 and defended through the July consolidation. A weekly close below it refills the court-ruling gap.\n- Price sits between that shelf and the August high, with the post-print advance retraced but the June structure intact. Mid-range is the honest description.\n- **The narrative is maturing.** Dated by the sequence — fresh attention 2026-06-10/06-11 (court ruling, +18.9% then extension), a second leg on the 2026-08-05 beat-and-raise, then a 15% giveback into 2026-08-14 with no follow-on headline. Coverage remains three analysts and the average target is within roughly a dollar of spot, so this is neither the accelerating phase of June nor a mainstream-saturated one.\n- Crowding and positioning observables, stated as observables: the best print of the year produced the 52-week high and was faded within two weeks; the consensus target of $5.17 sits above but near the $4.60 close; the filing feed reviewed for this update showed no recent insider transactions or equity issuance; RSI at 57.9 shows no momentum extreme; there is no earnings date inside the next 30 days to compress positioning against.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-16 → 2026-09-15: no confirmed company-dated event.** The Q2 print (2026-08-05) is done and the next scheduled corporate disclosure falls outside the window. This is a calendar void, and any move inside it is flow rather than news-driven.\n- **~2026-10-08 (est.):** CMS annual Star Ratings release for the next rating year. CMS has historically published in early October; the exact 2026 date was not confirmed in the sources reviewed.\n- **2026-10-15 (through 2026-12-07):** Medicare Advantage annual enrollment period opens — the mechanism that converts the 4.5-Star marketing position into 2027 membership.\n- **~2026-11-04 (est.):** Q3 2026 print, date unconfirmed. First read on whether the 87.6% BER and the raised guide hold.\n\n## Elapsed catalysts\n\n- **Ongoing, no scheduled date:** Eleventh Circuit appeal in *Clover Insurance Co. V. HHS* (notice of appeal filed 2026-07-21). No briefing schedule or argument date was public as of this note; an adverse or favorable order can land unannounced. *(passed 36d ago)*\n\n## What Would Change Our Mind\nThe cleanest break is legal, not financial: an Eleventh Circuit order vacating or remanding the S.D. Ga. Judgment, or CMS restoring H5141 to 3.5 Stars, removes the payment-year-2027 quality-bonus uplift that the June gap priced in — the estimated $120M cited by Modern Healthcare would come back out of the model. The second break is operational: Insurance BER printing above 87.6% at the Q3 report, or any trim to the $70–85M adjusted EBITDA guide, would show the raise was a first-half artifact. On the tape, a weekly close below $4.23 fills the 2026-06-10 court-ruling gap and ends the Star-Ratings breakout leg; below that shelf there is no defended structure between it and the pre-June range. In the other direction, a weekly close back above $5.41 on volume would re-date the narrative to accelerating and invalidate the maturing read stated here. A third condition worth naming: if a major carrier — Elevance or another — wins its own recalculation before the appeal resolves, the scarcity value of Clover's rating falls even if Clover's own case survives.\n\n## Correlation Notes\n- Direct comparables are the Medicare Advantage payers — UNH, HUM, ELV, ALHC. Star-ratings methodology is a shared input, so a plaintiff-favorable appellate outcome would lift the litigation optionality embedded in peers, and a CMS win would compress it sector-wide.\n- Policy beta: CMS finalized a +3% 2027 MA rate on 2026-04-07. Rate-notice and utilization headlines move the whole group before they move any single carrier's fundamentals.\n- Flow beta: former SPAC with retail-dominated turnover; on risk-on sessions the name trades with high-beta retail baskets independent of MA news, which is what produced the 2026-06-10 and 2026-08-05 single-session amplitudes.\n- Decorrelating factor: the Eleventh Circuit docket is Clover-specific. An order there moves this name against the group in either direction, which is why the sector chart is a poor proxy for where this narrative stands.",
  "first_seen": "2026-05-01",
  "last_analyzed": "2026-08-16T15:00:33+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}